Seven Fleet Capital Management LP acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) in the fourth quarter, HoldingsChannel reports. The firm acquired 79,560 shares of the company’s stock, valued at approximately $2,092,000. Tyra Biosciences comprises about 1.6% of Seven Fleet Capital Management LP’s holdings, making the stock its 8th largest position.
Other institutional investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $51,000. Chung Wu Investment Group LLC bought a new stake in shares of Tyra Biosciences in the fourth quarter worth about $53,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after purchasing an additional 534 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Tyra Biosciences by 27.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after purchasing an additional 2,766 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.
Tyra Biosciences Price Performance
Shares of Tyra Biosciences stock opened at $28.32 on Friday. The company has a 50-day moving average of $32.85 and a 200 day moving average of $31.24. Tyra Biosciences, Inc. has a 1 year low of $8.98 and a 1 year high of $40.65. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -12.99 and a beta of 0.75.
Insider Activity
In other news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the sale, the director owned 28,231 shares in the company, valued at $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.50% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have commented on TYRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. Bank of America lifted their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. JonesTrading began coverage on Tyra Biosciences in a research note on Wednesday. They set a “buy” rating and a $56.00 target price on the stock. Wolfe Research initiated coverage on Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group started coverage on Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.
Get Our Latest Stock Report on TYRA
Tyra Biosciences Company Profile
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report).
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
